Optimize, Automate, And Scale Closed-System MSC Expansion

As Mesenchymal Stem Cells (MSCs) become central to regenerative medicines and cell therapies, manufacturers must find ways to efficiently automate their production to meet market demand. Achieving target cell quantity and quality at an economical cost relies on moving to closed-system manufacturing that reduces risk and variability.

Unlike many immunotherapies, MSC applications require both basal media and a full complement of supplement growth factors, making a comprehensive, ready-to-use closed system critical. A novel dual-component kit is now available that streamlines the process for hollow-fiber platforms like Quantum Flex. This approach provides a complete, xeno-free, serum-free solution in a simple, bag-to-bioreactor construction. It is designed to support high expansion rates and viability, offer greater control by minimizing manual handling, and ensure a seamless, simple scale-up from research to commercial manufacturing.

Explore the full article to understand how a unified, closed-system approach can optimize, automate, and scale your MSC expansion.